MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

MAIA Biotechnology, Inc.AMEX: MAIA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $31.05M rose 468.6% year over year, ahead of the +129.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 546.6% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +468.6% holds above the trailing-twelve-month pace of +129.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.05M+546.6% QoQ
Last fiscal yearDec 2025
$17.91M-1.5% YoY
LTMMar 2026
$43.5M+129.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+468.6%——
1 year-1.5%——
3-year CAGR+12.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
17.91M USD
Year-over-year change
-1.5%
4-year CAGR
+6.3%

Financing Cash Flow vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 financing cash flow of $43.5M is the largest of the 7 companies compared; the peer median is $13.8M.
  • Its year-over-year change of +129.9% is the 4th highest of 6, against a peer median of +178.3%.
  • Over three fiscal years its annual growth of +12.8% compares with a peer median of +536.8%.
MAIA Competitors Peer median
Financing Cash Flow for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$43.5M +129.9%+12.8%—
VERUVeru Inc.LTM Mar 2026$23.37M +653.9%——
CELUCelularity Inc.LTM Dec 2025$18.65M +178.3%-46.2%70.2%
ANVSAnnovis Bio, Inc.LTM Mar 2026$18.52M -56.0%+19474.8%—
RNXTRenovoRx, Inc.LTM Mar 2026$9.08M -55.7%+536.8%609.9%
LTRNLantern Pharma Inc.LTM Mar 2026$1.5M +12391.6%——
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
Peer median (excluding MAIA) $13.8M+178.3%+536.8%340.1%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation2.72M2.32M3.09M1.91M2.63M
Change in Working Capital1.13M352.78K3.09M(1.24M)1.5M
Accounts Receivables0(269.4K)158.41K56.81K80.41K
Inventory00000
Accounts Payables805.52K211.35K471.9K(118.83K)519.72K
Other Working Capital320.23K410.83K2.46M(1.18M)899.19K
Other Non-Cash Items4.61M1M526.53K6.88M(579.4K)
Operating Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment7.43M0000
Common Stock Issued5.74M13.97M11.42M18.75M18.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities860.43K(1.5M)(2.15M)(578.1K)(617.13K)
Financing Cash Flow14.03M12.48M9.27M18.18M17.91M
Effect of Forex Changes0(4.43K)(117)(21.55K)(5.22K)
Net Change in Cash9.91M376.64K(3.8M)2.45M(943.27K)
Free Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.